...
首页> 外文期刊>Antimicrobial agents and chemotherapy. >In Vitro-In Vivo Discordance with Humanized Piperacillin-Tazobactam Exposures against Piperacillin-Tazobactam- Resistant/Pan-beta-Lactam-Susceptible Klebsiella pneumoniae Strains
【24h】

In Vitro-In Vivo Discordance with Humanized Piperacillin-Tazobactam Exposures against Piperacillin-Tazobactam- Resistant/Pan-beta-Lactam-Susceptible Klebsiella pneumoniae Strains

机译:在体外体内轻度与人源化的哌啶蛋白毒素曝光促使哌啶蛋白毒素抗性/泛β-内酰胺 - 易受肺炎塞氏菌菌株

获取原文
获取原文并翻译 | 示例
           

摘要

Recent findings have identified Klebsiella pneumoniae strains that are pan-beta-lactam susceptible (PBL-S) but piperacillin-tazobactam resistant (TZP-R) in vitro. We assessed the efficacy of a humanized exposure of piperacillin-tazobactam (TZP) against 12 TZP-R/PBL-S K. pneumoniae isolates in an immunocompromised murine lung infection model. Discordance between the in vitro resistance profile and the in vivo efficacy of human-simulated TZP exposures against this phenotypic profile was observed. Additional studies are required to define the clinical implications of these TZP-R/PBL-S strains.
机译:最近的发现已经确定了泛β-内酰胺易感(PBL-S)的Klebsiella肺炎菌株,但在体外耐哌啶蛋白酶抗性(TZP-R)。 我们评估了哌嗪-Tazobactam(TZP)对12 TZP-R / PBL-S K.肺炎群分离株在免疫鼠肺部感染模型中的疗效。 观察到体外抗性曲线与人模拟的TZP暴露的体内疗效与该表型细胞膜的体内效果之间的一种不等调。 需要额外的研究来确定这些TZP-R / PBL-S株的临床意义。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号